Literature DB >> 19101233

Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

John T Parissis1, Maria Nikolaou, Dionysia Birmpa, Dimitrios Farmakis, Ioannis Paraskevaidis, Vassiliki Bistola, Theodoros Katsoulas, Gerasimos Filippatos, Dimitrios T Kremastinos.   

Abstract

The Duke Activity Status Index (DASI) provides an accurate estimate of functional capacity in patients with chronic heart failure (HF). The aim of this study was to evaluate the prognostic value of the DASI against well-established prognostic factors in 130 consecutive patients hospitalized for worsening HF symptoms (mean age 64 +/- 12 years, mean left ventricular ejection fraction 26 +/- 7%), followed for 9 months for major cardiovascular events, defined as death or hospitalization for HF decompensation. During follow-up, 77 of 130 patients (59%) experienced major cardiovascular events after a median time of 60 days (range 5 to 220). Patients with eventful courses were in higher New York Heart Association functional classes (p = 0.001) and had shorter 6-minute walking distances (p = 0.041), lower ejection fractions (p <0.001), higher plasma B-type natriuretic peptide (BNP) levels at hospital admission and discharge (both p <0.001), and lower DASI scores (16 +/- 12 vs 25 +/- 17, p = 0.003). In multivariate Cox regression analysis including all these variables, only BNP level at discharge (p = 0.006) and DASI score (p = 0.047) were independently associated with event-free survival. A BNP cutoff of 697 pg/ml predicted future events with 59% sensitivity and 86% specificity, while a DASI score cutoff of 8 had 76% sensitivity and 25% specificity. The combination of the 2 cutoffs predicted events with 33% sensitivity and 95% specificity. Event-free survival was significantly lower in patients with the 2 markers positive (BNP >697 pg/ml and DASI score <8) compared with those with with 2 markers negative (63 +/- 27 vs 183 +/- 15 days, log-rank p <0.0001). In conclusion, functional status assessment by the DASI bears prognostic value, and its combination with plasma BNP may provide quite specific risk stratification in patients with chronic HF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101233     DOI: 10.1016/j.amjcard.2008.08.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.

Authors:  Nick Kontodimopoulos; Michalis Argiriou; Nikolaos Theakos; Dimitris Niakas
Journal:  Eur J Health Econ       Date:  2010-05-15

2.  Referral and use of heart failure clinics: what factors are related to use?

Authors:  Shannon Gravely; Liane Ginsburg; Donna E Stewart; Susanna Mak; Sherry L Grace
Journal:  Can J Cardiol       Date:  2012-02-25       Impact factor: 5.223

3.  Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index.

Authors:  Vichai Senthong; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  Am Heart J       Date:  2016-10-20       Impact factor: 4.749

4.  The effects of optimism and gratitude on adherence, functioning and mental health following an acute coronary syndrome.

Authors:  Rachel A Millstein; Christopher M Celano; Eleanor E Beale; Scott R Beach; Laura Suarez; Arianna M Belcher; James L Januzzi; Jeff C Huffman
Journal:  Gen Hosp Psychiatry       Date:  2016-08-30       Impact factor: 3.238

5.  Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure.

Authors:  Justin L Grodin; Frederik H Verbrugge; Stephen G Ellis; Wilfried Mullens; Jeffrey M Testani; W H Wilson Tang
Journal:  Circ Heart Fail       Date:  2016-01       Impact factor: 8.790

6.  Clinical predictors of response to anakinra in patients with heart failure.

Authors:  Justin M Canada; Benjamin W Van Tassell; Sanah Christopher; Claudia Oddi; Nayef A Abouzaki; Michael L Gambill; George Mueller; Ryan Melchior; Keyur B Shah; Charles A Dinarello; Antonio Abbate; Ross Arena
Journal:  Int J Cardiol       Date:  2014-03-15       Impact factor: 4.164

7.  Usefulness of Relative Hypochromia in Risk Stratification for Nonanemic Patients With Chronic Heart Failure.

Authors:  Muhammad Hammadah; Marie-Luise Brennan; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  Am J Cardiol       Date:  2016-01-28       Impact factor: 2.778

8.  Design and baseline data from the Gratitude Research in Acute Coronary Events (GRACE) study.

Authors:  Jeff C Huffman; Eleanor E Beale; Scott R Beach; Christopher M Celano; Arianna M Belcher; Shannon V Moore; Laura Suarez; Parul U Gandhi; Shweta R Motiwala; Hanna Gaggin; James L Januzzi
Journal:  Contemp Clin Trials       Date:  2015-07-10       Impact factor: 2.226

9.  Medication adherence, social support, and event-free survival in patients with heart failure.

Authors:  Jia-Rong Wu; Susan K Frazier; Mary Kay Rayens; Terry A Lennie; Misook L Chung; Debra K Moser
Journal:  Health Psychol       Date:  2012-07-02       Impact factor: 4.267

10.  Prognostic value of estimating functional capacity with the use of the duke activity status index in stable patients with chronic heart failure.

Authors:  Justin L Grodin; Muhammad Hammadah; Yiying Fan; Stanley L Hazen; W H Wilson Tang
Journal:  J Card Fail       Date:  2014-08-28       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.